Company intelligence

PHVS

Pharvaris N.V. · NASDAQ · Healthcare

Price$38.86+2.21% · +$0.84

Market cap2.72BEquity value

P / E-12.2Trailing ratio

Volume997.91KLatest session

Market data

PHVS price chart

TradingView

Related signals

1 min delayed

Browse public PHVS signals with their source context and measured market impact. Open any signal for its permanent analysis page.

PHVSSep 8, 2026+7.38% since signal

Pharvaris' oral HAE therapy hits primary endpoint in pivotal trial

Pharvaris reported that its oral medicine for hereditary angioedema met the primary endpoint in a Phase 3 trial, marking a pivotal step toward potential regulatory filing. The positive result could unlock a pathway to market and upside for PHVS if the company can confirm safety and secondary efficacy signals. Investors should watch for additional data and timing of next catalyst.

View signal analysis

PHVSDec 3, 2025-1.74% since signal

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

PHVS released positive data on deucrictibant for HAE treatment. Deucrictibant showed significant improvement over placebo with faster symptom relief. Plans for marketing authorization applications to start in 2026. Stock price increased by 12.32%, indicating strong investor interest. Ongoing competition includes treatments from Ionis and KalVista Pharmaceuticals.

View signal analysis

Research